GenSight Biologics is a leading brand in the field of gene therapy against blindness. With a focus on innovative technologies, the company is dedicated to developing treatments for various vision-related diseases. GenSight Biologics targets diseases such as Leber Hereditary Optic Neuropathy (LHON), Retinitis Pigmentosa (RP), and Geographic Atrophy in Dry-AMD.

Through their groundbreaking gene therapy and mitochondrial targeting sequence (MTS) technologies, GenSight Biologics aims to restore vision and improve the quality of life for patients. Additionally, the company utilizes the emerging field of optogenetics to further enhance their treatments. With clinical development underway and a strong focus on research, GenSight Biologics is committed to bringing safe and effective therapies to patients.

Their current clinical trials include the evaluation of GS010 for LHON and the ongoing PIONEER Phase I/II trial for GS030. Headquartered in Paris, France, and with a presence in New York City, GenSight Biologics is at the forefront of advancing gene therapy in the fight against blindness. Contact them today to learn more about their groundbreaking technologies and innovative approach to vision restoration